Highlights Molecure S.A.

Equities

MOC

PLONCTH00011

Market Closed - Warsaw S.E. Other stock markets 11:55:41 2024-06-04 EDT			5-day change	1st Jan Change
15.22 ^PLN	-0.26%		+1.47%	-21.95%

05-21	Molecure S.A. Receives Approval to Initiate A Phase II Clinical Trial for OATD-01 for the Treatment of Pulmonary Sarcoidosis in Selected Countries of the European Union and Norway	CI
05-17	Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Molecure S.A. Receives Approval to Initiate A Phase II Clinical Trial for OATD-01 for the Treatment of Pulmonary Sarcoidosis in Selected Countries of the European Union and Norway	05-21	CI
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-17	CI
Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis	03-22	CI
Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I	01-16	CI
Molecure S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-30	CI
Molecure S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Poland's Molecure Gets US FDA Clearance for Mid-stage Trial of Potential Pulmonary Sarcoidosis Treatment	23-07-24	MT
Molecure S.A. Receives Clearance from the U.S. Food and Drug Administration on its Investigational New Drug Application to Conduct Phase II Clinical Testing of OATD-01	23-07-24	CI
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Molecure S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Molecure Announces First Patient Dosed in Phase I Trial with Novel, First-In-Class Dual Arginase Inhibitor OATD-02 for the Treatment of Cancer	23-03-08	CI
Molecure S.A. to Begin Clinical Development of Novel Dual Arginase Inhibitor Oatd-02 for the Treatment of Cancer After Gaining Permission to Conduct First Clinical Trial in Poland	22-11-28	CI
Molecure S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-10-30	CI
Molecure S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-28	CI
Molecure S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
OncoArendi Therapeutics S.A. Announces A License Option Agreement with University of Michigan	22-03-11	CI
OncoArendi Therapeutics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-10-28	CI
OncoArendi Therapeutics SA and Galapagos Enter into Exclusive Collaboration on Chitinase Inhibitors in Fibrosis	20-11-05	CI
Oncoarendi Therapeutics S.A. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-10-30	CI
Oncoarendi Therapeutics S.A. Reports Earnings Results for the Half Year Ended June 30, 2020	20-09-24	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Molecure S.A.

Equities

MOC

PLONCTH00011

Highlights

Filters